| Disease | SUGGEST THAT SJW DECREASES PLASMA QUAZEPAM CONCENTRATIONS, PROBABLY BY ENHANCING CYP3A4 ACTIVITY, BUT DOES NOT INFLUENCE THE PHARMACODYNAMIC EFFECTS OF THE DRUG.
P<0.01, MENTAL SLOWNESS; P<0.01,CALMNESS; P<0.05, DISCONTENTMENT; P<0.01). ON THE OTHER HAND, SJW, BUT NOT QUAZEPAM IMPAIRED PSYCHOMOTOR PERFORMANCE IN THE DSST TEST. SJW DID NOT INFLUENCE THE PHARMACODYNAMIC PROFILE OF QUAZEPAM. THESE RESULTS
LOWER THAN THOSE AFTER PLACEBO. THE URINARY RATIO OF 6 BETA-HYDROXYCORTISOL TO CORTISOL, WHICH REFLECTS CYP3A4 ACTIVITY, ALSO INCREASED AFTER DOSING WITH SJW. QUAZEPAM, BUT NOT SJW, PRODUCED SEDATIVE-LIKE EFFECTS IN THE VAS TEST (DROWSINESS;
TWO TREATMENTS. BLOOD SAMPLES WERE OBTAINED DURING A 48 H PERIOD AND URINE WAS COLLECTED FOR 24 H AFTER EACH DOSE OF QUAZEPAM. SJW DECREASED THE PLASMA QUAZEPAM CONCENTRATION. THE CMAX AND AUC(0-48) OF QUAZEPAM AFTER SJW WERE SIGNIFICANTLY
13 HEALTHY SUBJECTS TOOK A SINGLE DOSE OF QUAZEPAM 15 MG AFTER TREATMENT WITH SJW (900 MG DAY (-1)) OR PLACEBO FOR 14 DAYS. THE STUDY WAS PERFORMED IN A RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER DESIGN WITH AN INTERVAL OF 4 WEEKS BETWEEN THE |